This study focused on circulating levels of asprosin, clusterin, ZAG, NF-κB, and PPAR-γ in diabetic patients, evidencing remarkable changes in such biomarkers, with special emphasis on the relationships with complications related to T2DM. This evidence concerns the gene CLU and type 2 diabetes mellitus.